OKUR
OnKure Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.58
+0.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 203.0K | 830.0K | — | — | — |
| Gross Profit | (203.0K) | (830.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 47.0M | 48.3M | 43.8M | 32.1M | 25.9M |
| SG&A Expense | 15.2M | 14.7M | 10.6M | 4.8M | 3.9M |
| General & Admin Expense | 15.2M | 14.7M | 10.6M | 4.8M | 3.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (203.0K) | (830.0K) | — | — | — |
| Total Operating Expenses | 61.9M | 62.1M | 54.4M | 36.9M | 29.8M |
| Cost and Expenses | 62.1M | 63.0M | 54.4M | 36.9M | 29.8M |
| Operating Income (EBIT) | (62.1M) | (63.0M) | (54.4M) | (36.9M) | (29.8M) |
| Non-Operating | |||||
| Interest Income | 3.4M | 3.4M | 2.0M | 1.6M | 254.0K |
| Interest Expense | 8.0K | — | 300.0K | — | — |
| Net Interest Income | 3.4M | 3.4M | 1.7M | 1.6M | 254.0K |
| Other Non-Op Income/Expense | 3.4M | 3.4M | 1.7M | 1.6M | 254.0K |
| Non-Operating Income (excl Interest) | (3.4M) | (3.4M) | (2.0M) | (1.6M) | (254.0K) |
| EBT (Pre-Tax Income) | (58.7M) | (59.5M) | (52.7M) | (35.3M) | (29.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (58.7M) | (59.5M) | (52.7M) | (35.3M) | (29.5M) |
| Earnings from Cont. Ops | (58.7M) | (59.5M) | (52.7M) | (35.3M) | (29.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (58.7M) | (59.5M) | (52.7M) | (35.3M) | (29.5M) |
| Per Share | |||||
| Basic EPS | ($3.50) | ($4.40) | ($3.95) | ($2.65) | ($2.21) |
| Diluted EPS | ($3.50) | ($4.40) | ($3.95) | ($2.65) | ($2.21) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 49.9M | 13.5M | 13.3M | 13.3M | 13.3M |
| Diluted Shares Outstanding | 49.9M | 13.5M | 13.3M | 13.3M | 13.3M |
| Profitability Metrics | |||||
| EBITDA | (58.1M) | (58.7M) | (51.7M) | (34.8M) | (29.1M) |
| D&A | 609.0K | 830.0K | 662.0K | 560.0K | 387.0K |
| EBIT | (58.7M) | (59.5M) | (52.4M) | (35.3M) | (29.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026